| Mark D Hegewald, MD | |
|
34612 6th Ave S, Suite 200, Federal Way, WA 98003-8723 | |
| (253) 661-2594 | |
| (253) 661-2694 |
| Full Name | Mark D Hegewald |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 41 Years |
| Location | 34612 6th Ave S, Federal Way, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700825304 | NPI | - | NPPES |
| 1427128198 | Other | WA | GROUP NPI |
| 1056662 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | MD00025475 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Surgical Associates Northwest Pc | 3971596024 | 12 |
News Archive
The largest and most comprehensive mental health survey of college students in the US reveals that students who identify as transgender, gender nonconforming, genderqueer, and nonbinary face enormous mental health disparities relative to their peers.
Chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, is a chronic lung disease that makes it hard to breathe. The disease affects millions of Americans and is the fourth leading cause of disease-related death in the U.S. People with COPD have a higher risk of more severe illness from COVID-19 due to their existing lung problems.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
In the course of a study conducted throughout Germany, medical professionals have compared different treatment methods for Neuromyelitis optica, an inflammatory disease of the central nervous system. It turned out that the best results were not achieved with conventional steroid therapy. Under the auspices of the Ruhr-Universität Bochum and the Hannover Medical School, the team published their findings in the journal Annals of Neurology.
› Verified 8 days ago
| Entity Name | Surgical Associates Northwest Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427128198 PECOS PAC ID: 3971596024 Enrollment ID: O20040406000126 |
News Archive
The largest and most comprehensive mental health survey of college students in the US reveals that students who identify as transgender, gender nonconforming, genderqueer, and nonbinary face enormous mental health disparities relative to their peers.
Chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, is a chronic lung disease that makes it hard to breathe. The disease affects millions of Americans and is the fourth leading cause of disease-related death in the U.S. People with COPD have a higher risk of more severe illness from COVID-19 due to their existing lung problems.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
In the course of a study conducted throughout Germany, medical professionals have compared different treatment methods for Neuromyelitis optica, an inflammatory disease of the central nervous system. It turned out that the best results were not achieved with conventional steroid therapy. Under the auspices of the Ruhr-Universität Bochum and the Hannover Medical School, the team published their findings in the journal Annals of Neurology.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark D Hegewald, MD 34612 6th Ave S, Suite 200, Federal Way, WA 98003-8723 Ph: (253) 661-2594 | Mark D Hegewald, MD 34612 6th Ave S, Suite 200, Federal Way, WA 98003-8723 Ph: (253) 661-2594 |
News Archive
The largest and most comprehensive mental health survey of college students in the US reveals that students who identify as transgender, gender nonconforming, genderqueer, and nonbinary face enormous mental health disparities relative to their peers.
Chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, is a chronic lung disease that makes it hard to breathe. The disease affects millions of Americans and is the fourth leading cause of disease-related death in the U.S. People with COPD have a higher risk of more severe illness from COVID-19 due to their existing lung problems.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
In the course of a study conducted throughout Germany, medical professionals have compared different treatment methods for Neuromyelitis optica, an inflammatory disease of the central nervous system. It turned out that the best results were not achieved with conventional steroid therapy. Under the auspices of the Ruhr-Universität Bochum and the Hannover Medical School, the team published their findings in the journal Annals of Neurology.
› Verified 8 days ago
Daniel W Kozie, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 34612 6th Ave S, Federal Way, WA 98003 Phone: 253-661-2594 Fax: 253-661-2694 | |
Ryan E Stern, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 34612 6th Ave S, Suite 110, Federal Way, WA 98003 Phone: 253-661-2594 | |
Rodney Teasley, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 34509 9th Ave S Ste 202, Federal Way, WA 98003 Phone: 253-942-2270 Fax: 360-377-1558 | |
David Michael Johnson, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 34612 6th Ave S Ste 200, Federal Way, WA 98003 Phone: 253-661-2520 Fax: 253-661-2694 | |
Dr. Kirby J Lautman, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 34612 6th Ave S, Suite 200, Federal Way, WA 98003 Phone: 253-661-2594 Fax: 253-661-2694 | |
Mark B Emery, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 34612 6th Ave S, Federal Way, WA 98003 Phone: 253-661-2594 Fax: 253-661-2694 |